Human Genome Sciences Inc. (HGSI) (1 Viewer)

[DickSIM]

Crossing Their Fingers
July 16, 2009

Human Genome Sciences plans to release late-stage clinical data on Benlysta, its experimental drug for lupus, on Monday, reports Dow Jones Newswires. The story adds that lupus is "a notoriously hard-to-treat autoimmune disease that hasn't seen a new therapy in decades." Human Genome Sciences partnered with GlaxoSmithKline and worked closely with FDA to design its phase III trial after the phase II trial failed. The article says that if this first trial fails — Barclays analyst Jim Birchenough estimates an 85 percent chance of failure — the company's stock will likely drop to about $1; but if it meets its endpoints, the stock could reach higher than $10.

 

[coxy]

sta cosa ,,,, nun me piace

bahhh ,,, troppe possibilità di entrare ,,,, a tutti

concordo non si offre un pasto gratis a tutti. Ma se contrariamente
alle aspettative dei dirigenti oltre al lupus ci fossero altre malattie autoimmuni?
GSK sperimentava l'artrite reumatoide, se non erro.
Cos'altro c'era?
Magolibero dov'è?

 

[DickSIM]

concordo non si offre un pasto gratis a tutti. Ma se contrariamente
alle aspettative dei dirigenti oltre al lupus ci fossero altre malattie autoimmuni?
GSK sperimentava l'artrite reumatoide, se non erro.
Cos'altro c'era?
Magolibero dov'è?

HGS has substantial financial rights to a number of products in the GSK clinical pipeline. Two of these have advanced to Phase 3 development.

Darapladib is a selective and orally active inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that has been identified in clinical trials as an independent risk factor for coronary heart disease and ischemic stroke. GSK has initiated a pivotal Phase 3 trial to evaluate the efficacy and safety of treatment with the investigational Lp-PLA2 inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary heart disease. Darapladib was discovered by GSK based on HGS technology, and it has the potential to be an important new treatment for the prevention of cardiovascular risk.

Syncria® (albiglutide) is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. GSK has initiated a Phase 3 clinical trial program to evaluate the safety and efficacy of Syncria in the long-term treatment of type 2 diabetes mellitus. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004.

For additional information about any of the GSK products to which HGS has rights, please contact GSK directly.

 

[viralic]

STRANAMENTE ,,,, devo concordare

.............Quando concorderemo anche su Nicox ???

 

[DickSIM]

una domanda.
20 milioni di azioni in due ore. che significa? qualcuno accumula o qualcuno vuol far credere di accumulare? secondo te puo' essere che alcuni già sanno? sarebbe unfair

bhà io nn mi stupisco più di niente.........

potrebbe pure essere che domani esca la news, invece che lunedi.

anche perchè con sti volumi, i big stan comprando........qualcuno però esce, alla vigilia? o comprano il flottantea man bassa?
come già detto opto per qualche ricopertura sicura, acqua se nn sbagli qui ci stavano shortando alla grande o stanno prendendo la rincorsa per il colpo di grazia!
anche perchè qui il 63% del cs è nelle mani di istituzionali.....mica pizza e fichi

 

[coxy]

HGS has substantial financial rights to a number of products in the GSK clinical pipeline. Two of these have advanced to Phase 3 development.

Darapladib is a selective and orally active inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that has been identified in clinical trials as an independent risk factor for coronary heart disease and ischemic stroke. GSK has initiated a pivotal Phase 3 trial to evaluate the efficacy and safety of treatment with the investigational Lp-PLA2 inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary heart disease. Darapladib was discovered by GSK based on HGS technology, and it has the potential to be an important new treatment for the prevention of cardiovascular risk.




Syncria® (albiglutide) is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. GSK has initiated a Phase 3 clinical trial program to evaluate the safety and efficacy of Syncria in the long-term treatment of type 2 diabetes mellitus. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004.

For additional information about any of the GSK products to which HGS has rights, please contact GSK directly.

sto pensando (allucinando forse) all'artrite reumatoide ed alla sclerosi multipla. Forse è il caldo.... vado a fare un tuffo, poi ci ripenso con calma e a temperature da prosecco.

 

[DickSIM]

sto pensando (allucinando forse) all'artrite reumatoide ed alla sclerosi multipla. Forse è il caldo.... vado a fare un tuffo, poi ci ripenso con calma e a temperature da prosecco.

a qui il tecnico-tattico sei tu! prenditi il tempo che ti serve tanto non si scappa!

 

[DickSIM]

qui se si mettono a tirare ancora cannellate da 200-300k al meglio arriviamo a 5$!!!!!!!!!

inizia a bruciarmi il deretano...........

 

[acqua+]

qui se si mettono a tirare ancora cannellate da 200-300k al meglio arriviamo a 5$!!!!!!!!!

inizia a bruciarmi il deretano...........

nun me garba ,,, sta storia

a 3,90 me vendo metà ,,,, peraltro, da 0,70 di strada ne ha fatta

,,, e anche di gain


... girerò una parte ,,, sulla coxinella

 

[DickSIM]

nun me garba ,,, sta storia

a 3,90 me vendo metà ,,,, peraltro, da 0,70 di strada ne ha fatta

,,, e anche di gain


... girerò una parte ,,, sulla coxinella

caxxxxxxxxxxxxxxxo..............se vendi tu la fai crollareeeeee!